HNRNPA2B1 and hepatocellular carcinoma: Based upon the accuracy of the established model for estimating OS in patients with HBV-related HCC in the early TNM stage, our study paves the way for further investigations on both RBM15 and HNRNPA2B1 as prognostic biomarkers and therapeutic targets.